Melane Sampson, Author at BioTuesdays

Executive Moves

BioSig appoints John Kowalski as VP of sales

BioSig Technologies (NASDAQ:BSGM) named John Kowalski as VP of sales to lead the commercial launch of the PURE EP signal acquisition and processing system, which is designed to improve the diagnosis and treatment of...

February 5, 2019

Developments

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Rigel Pharmaceuticals (NASDAQ:RIGL) entered an exclusive license and supply agreement with Grifols (MCE:GRF; MCE:GRF.P; NASDAQ:GRFS) of Spain to commercialize fostamatinib disodium hexahydrate in all potential...

January 23, 2019

Developments

Canopy Growth receives NY hemp license; plans to establish U.S. commercial operations

Canopy Growth (TSX:WEED) (NYSE:CGC) received a licence from New York State to process and produce hemp and will establish large-scale hemp extraction and product manufacturing in the state. Subject to board approval of...

January 14, 2019

Developments

Fibrocor, Galapagos NV in development pact for fibrotic diseases

Closely-held Fibrocor Therapeutics, and Galapagos NV (Euronext, NASDAQ:GLPG), of Belgium formed a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs. In 2017, MaRs...

January 8, 2019

Developments

Scientus Pharma receives Health Canada approval to sell dried cannabis

Closely-held Scientus Pharma received authorization under Health Canada’s cannabis regulations for the sale of cannabis for medical purposes and to modify its processor licence to sell dried and fresh cannabis products...

January 3, 2019

Developments

BeyondSpring receives U.S. composition of matter patent for Plinabulin

BeyondSpring (NASDAQ:BYSI) received a new composition of matter patent for its lead asset, Plinabulin, from the U.S. Patent and Trademark Office. As a polymorph, Pinabulin can be converted into multiple crystalline...

December 21, 2018

Developments

IntelGenx in pact with Gensco Pharma to market RIZAPORT in U.S.

IntelGenx (TSX-V:IGX; OTCQX:IGXT) signed a definitive licensing, development and supply agreement with Gensco Pharma, a specialty pharmaceutical company, for the exclusive commercialization of RIZAPORT in the U.S. “With...

December 12, 2018

Developments

Scientus Pharma receives U.S. patent for cannabis extraction technology

Closely-held Scientus Pharma, through its HydRx Farms unit, received a U.S. patent that provides intellectual property protection for its decarboxylation method for extraction and activation of active pharmaceutical...

December 5, 2018

Developments

Canopy Growth in equity investment, supply deal, strategic partnership with 48North

Canopy Growth (TSX:WEED; NYSE: CGC) inked an investment financing, and partnership and a supply agreement with 48North Cannabis (TSXV:NRTH). Under the supply accord, 48North would supply Canopy with dried cannabis...

December 3, 2018

Developments

Lobo Genetics going public in RTO of Cassowary Capital

Closely-held Lobo Genetics entered into a non-binding letter of intent with Cassowary Capital (TSXV:BIRD) that will result in a reverse takeover of Cassowary by Lobo. Cassowary is a capital pool company on the TSX...

November 22, 2018

Author - Melane Sampson

BioSig appoints John Kowalski as VP of sales

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Canopy Growth receives NY hemp license; plans to establish U.S. commercial operations

Fibrocor, Galapagos NV in development pact for fibrotic diseases

Scientus Pharma receives Health Canada approval to sell dried cannabis

BeyondSpring receives U.S. composition of matter patent for Plinabulin

IntelGenx in pact with Gensco Pharma to market RIZAPORT in U.S.

Scientus Pharma receives U.S. patent for cannabis extraction technology

Canopy Growth in equity investment, supply deal, strategic partnership with 48North

Lobo Genetics going public in RTO of Cassowary Capital

General

More